CN112195239B - 一种食管鳞癌转移组织及血清外泌体标志物及其应用 - Google Patents
一种食管鳞癌转移组织及血清外泌体标志物及其应用 Download PDFInfo
- Publication number
- CN112195239B CN112195239B CN202010149018.3A CN202010149018A CN112195239B CN 112195239 B CN112195239 B CN 112195239B CN 202010149018 A CN202010149018 A CN 202010149018A CN 112195239 B CN112195239 B CN 112195239B
- Authority
- CN
- China
- Prior art keywords
- circ
- reagent
- hsa
- esophageal squamous
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 54
- 210000002966 serum Anatomy 0.000 title claims abstract description 45
- 210000001519 tissue Anatomy 0.000 title claims abstract description 45
- 206010041823 squamous cell carcinoma Diseases 0.000 title claims abstract description 35
- 230000001394 metastastic effect Effects 0.000 title abstract description 8
- 206010061289 metastatic neoplasm Diseases 0.000 title abstract description 8
- 239000003550 marker Substances 0.000 title abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 47
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 238000003745 diagnosis Methods 0.000 claims abstract description 17
- 206010027476 Metastases Diseases 0.000 claims abstract description 16
- 230000009401 metastasis Effects 0.000 claims abstract description 16
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims abstract description 5
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims abstract description 5
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims abstract description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 238000011529 RT qPCR Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000010839 reverse transcription Methods 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 230000000683 nonmetastatic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101100283975 Bos taurus GSTM1 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种食管鳞癌转移组织及血清外泌体标志物及其应用。检测hsa_circ_0081964的试剂在制备利用组织或血清外泌体诊断食管鳞癌淋巴结转移情况的试剂中的应用。一种食管鳞癌转移情况的血清外泌体辅助诊断试剂盒,包含SEQ ID NO.2和SEQ ID NO.3所示的hsa_circ_0081964特异性引物。本发明提供的组织及血清外泌体circRNA检测方法和试剂盒,能够从样本中准确地检测食管鳞癌组织及外泌体has_circ_0081964,为食管鳞癌淋巴结转移情况提供方便可行的检测方法,为临床上合适的治疗方案的选择提供帮助。
Description
技术领域
本发明属于生物医药检测领域,涉及一种食管鳞癌转移组织及血清外泌体标志物及其应用。
背景技术
我国是全世界食管癌高发国家,其发病率居我国恶性肿瘤第5位,病死率第4位,90%为食管鳞癌。目前食管癌的确诊依靠组织活检,但确诊时大多病人已是中晚期,预后较差。治疗上以手术切除和放化疗为主要手段。但手术对局部晚期食管癌患者疗效较差,放化疗对人体正常功能损伤较大。因此,建立一种微创、早期、灵敏和方便的的检测手段是必要的。
外泌体指细胞释放到细胞外环境的包含了复杂核酸、蛋白质、脂质的,直径为30-100nm脂质双膜微小膜泡,能作为信号分子在生理和病理过程中发挥着重要作用。外泌体是肿瘤微环境的重要组成部分,介导细胞间通信,参与组织浸润,转移,血管生成和耐药等肿瘤生物学过程。
circRNA是一种特殊的具有共价闭合环状结构的非编码RNA,具有疾病特异性以及组织发生、发展阶段特异性,参与肿瘤的增殖、凋亡、迁移和侵袭等多种生理和病理过程的生物调控。同时,circRNA具有高度的稳定性和保守型,且在各种组织细胞和人体体液中广泛分布。鉴于以上特点,circRNA有望成为具有前景的新型疾病分子标志物。有分析显示肿瘤组织及血清外泌体中circRNA稳定且丰富,是肿瘤诊断的理想标志物。
目前存在的问题是
(1)目前针对组织及外泌体内circRNA作为肿瘤诊断标志物的分析仅有少数报道,且大多利用高通量测序技术对组织circRNA进行表达谱分析,成本较高,可用于诊断食管鳞癌的组织及血清外泌体circRNA分子尚不清楚。
(2)传统trizol法无法保证在微量血清外泌体中提取circRNA的浓度以及纯度。
解决上述技术问题的难度:目前,急需开发一种简便的提取和检测组织及血清外泌体circRNA方法,既能保证提取的浓度和纯度较好,又能保证检测的准确性。解决上述技术问题的意义:能为食管鳞癌转移早期诊断提供新的潜在外泌体circRNA标志物和临床实验室检测方法,也能为发掘和分析更多组织及血清外泌体circRNA应用于肿瘤标志物提供帮助。
发明内容
本发明的目的是针对现有技术的上述不足,提供hsa_circ_0081964作为检测靶标在制备利用组织或血清外泌体诊断食管鳞癌淋巴结转移情况的试剂中的应用。
本发明的另一目的是提供检测hsa_circ_0081964的试剂的应用。
本发明的又一目的是提供一种食管鳞癌转移情况的辅助诊断试剂盒。
本发明的目的可通过以下技术方案实现:
hsa_circ_0081964作为检测靶标在制备利用组织或血清外泌体诊断食管鳞癌淋巴结转移情况的试剂中的应用。
检测hsa_circ_0081964的试剂在制备利用组织或血清外泌体诊断食管鳞癌淋巴结转移情况的试剂中的应用。
所述的试剂优选hsa_circ_0081964特异性引物。
所述的hsa_circ_0081964特异性引物序列进一步优选如SEQ ID NO.2和SEQ IDNO.3所示。
一种食管鳞癌转移情况的血清外泌体辅助诊断试剂盒,包含SEQ ID NO.2和SEQID NO.3所示的hsa_circ_0081964特异性引物。
所述的试剂盒优选包含两部分:
A.血清外泌体circRNA提取试剂,包括:
(1)提取血清外泌体所需试剂:GSTM Exosome Isolation Reagent;
(2)提取外泌体circRNA所需试剂:氯仿、无水乙醇、miRNeasy Serum/Plasma Kit;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂,
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及B-actin特异性引物。
一种食管鳞癌转移情况的组织辅助诊断试剂盒,包含SEQ ID NO.2和SEQ ID NO.3所示的hsa_circ_0081964特异性引物。
所述的试剂盒,优选包含两部分:
A.提取组织circRNA所需试剂,包括:TrIzol Reagent、氯仿、异丙醇;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂,
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及B-actin特异性引物。
有益效果:
本发明发现食管鳞癌组织及血清外泌体中has_circ_0081964对于食管鳞癌转移诊断的价值。提供的组织及血清外泌体circRNA检测方法和试剂盒,能够从样本中准确地检测食管鳞癌组织及外泌体has_circ_0081964,为食管鳞癌淋巴结转移情况提供方便可行的检测方法,为临床上合适的治疗方案的选择提供帮助。
附图说明
图1是本发明实施例提供的Nanodrop仪检测所分离的组织及血清外泌体RNA的浓度和纯度示意图。
图2是本发明实施例提供的实时荧光定量PCR检测hsa_circ_0081964和β-actin的扩增曲线及熔解曲线图。
图3是本发明实施例提供的PCR产物琼脂糖凝胶电泳示意图。
A:B-actin B:血清circRNA C:组织circRNA
图4是本发明实施例提供的实时荧光定量PCR比较食管鳞癌转移患者与非转移患者组织及血清血清外泌体hsa_circ_0081964表达差异示意图。
图5是本发明实施例提供的ROC曲线分析食管鳞癌组织(A图)及血清外泌体(B图)hsa_circ_0081964对食管鳞癌转移情况诊断的特异性和灵敏度示意图。
具体实施方式
实施例1
一种食管鳞癌转移情况的血清外泌体辅助诊断试剂盒,包含两部分:
A.血清外泌体circRNA提取试剂,包括:
(1)提取血清外泌体所需试剂:GSTM Exosome Isolation Reagent,购自吉赛公司,货号E3002;
(2)提取外泌体circRNA所需试剂:氯仿、无水乙醇、miRNeasy Serum/Plasma Kit购自QIAGNE且货号217184;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂:Primescript RT reagent Kit,购自Takara公司,货号RR036A
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及β-actin特异性引物。
hsa_circ_0081964特异性引物序列如SEQ ID NO.2和SEQ ID NO.3所示;
β-actin特异性引物序列如SEQ ID NO.4和SEQ ID NO.5所示。
实施例2
一种食管鳞癌转移情况的组织辅助诊断试剂盒,包含两部分:
A.提取组织circRNA所需试剂,包括:TrIzol Reagent,购自赛默飞世尔公司,货号15596018、氯仿、异丙醇;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂:Primescript RT reagent Kit,购自Takara公司,货号RR036A
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及β-actin特异性引物。
hsa_circ_0081964特异性引物序列如SEQ ID NO.2和SEQ ID NO.3所示;
β-actin特异性引物序列如SEQ ID NO.4和SEQ ID NO.5所示。
实施例3
(1)血清的采集与制备1)以血浆分离胶抗凝管采集肘静脉血5ml,采血后立即轻柔颠倒5次以充分混匀;2)室温静置30min后,以水平离心机室温3000r/min离心15min使血清与血凝块被分离胶完全分隔;3)以微量移液器将上层血清转移并分装至1.5ml进口EP管中(300μl/管);
(2)血清外泌体沉淀与提取
加入1ml GSTM Exosome Isolation Reagent,轻柔吹打混匀;置4℃静置过夜以充分沉淀外泌体;
3)以4℃,1500g离心混合物30min,将沉淀物离心至管底;去除上清,再以4℃,1500g离心5min去除残余液体,避免触碰管底沉淀;
4)以50-250ul灭菌1xPBS重悬管底外泌体沉淀,4℃放置10min以溶解外泌体,并待进一步使用。
(3)外泌体circRNA提取
1)将上述外泌体加入600μl QIAzol裂解液,充分颠倒混匀,并在室温静置5min;加入与外泌体体积相等的氯仿,剧烈涡旋震荡15s,并放置室温静置平衡2-3min;
2)置离心机4℃,12000g离心15min;以微量移液器吸取上清至新进口EP管中,加入1.5倍体积无水乙醇,颠倒混匀;
3)先移取700μl混合液于外套有收集管的分离柱中,4℃,12000g,15s离心,弃收集管中废液,再将剩余混合液加入分离柱,重复上述操作;
4)向分离柱中加入700μl RWT溶液,4℃,12000g,15s离心,弃收集管中废液;5)再向分离柱中加入700μl RPE溶液,4℃,12000g,15s离心,弃收集管中废液;6)向分离柱中加入500μl以无RNase酶水配制的80%乙醇,4℃,12000g,2min离心,弃收集管;
5)将上述分离柱放入配套新收集管中,4℃,12000g,5min,弃收集管;将分离柱放入配套新进口EP管中,以微量移液器对准分离柱中间加入14μl无RNase酶水,静置3-5min,以充分湿润和溶解RNA;
6)以离心机4℃,12000g,5min离心收集提取和分离出的circRNA;-80℃保存或置4℃待立即使用。
(4)组织circRNA提取
1)将0.1g液氮中取出的新鲜食管鳞癌组织,放入预装1mlTrizol裂解液的EP管中,然后将EP管置于组织匀浆机,调整为30转/min,震动2min;2)加入上清体积1/5的氯仿,震荡1min使其震荡混匀,将EP管放置于离心机中,120X100g离心15min。离心后,根据离心分层(水相-白色沉淀-红色有机物)小心取出上清液加入到另一新离心管中;3)加入等体积的异丙醇,上下轻颠倒摇匀,静置10min;4)将EP管置于离心机中离心,4℃,12,000rpm,15min;5)观察是否有沉淀,加入1ml75%的乙醇后置于离心机中,7500g,4℃,离心5min。然后弃上清,将带有沉淀的EP管放置于通风橱中晾干;6)向EP管内加入DEPC水溶解,于-80℃保存。使用Nano-drop仪器检测提取的RNA浓度,测定OD260和OD280值。正常的RNA浓度范围500-1500ng/μL,OD260/OD280比值均在1.8-2.0左右。RNA的浓度如图1所示。
实施例4组织及血清外泌体hsa_circ_0081964的检测和鉴定
(1)cDNA的制备
注:在此体系中RNA模版量不应超过2.5ug,否则会影响反应的结果。
逆转录反应,条件如下:
37℃ 15min;
85℃ 5sec
4℃
(2)实时荧光定量qPCR
应用QuantStudioTM6Flex系统经行qRT-PCR实验。反应体系如下:
qRT-PCR反应体系的配制
qRT-PCR反应条件
PCR结果分析:qPCR结果显示的扩增曲线和溶解曲线如图2所示
Tris-硼酸电泳缓冲液(TBE)的贮存浓度为5xTBE缓冲液,其工作浓度为0.5xTBE缓冲液。5xTBE缓冲液的配方为,将54g Tris,27.5g硼酸,20ml pH为0.8的EDTA加入1000ml的蒸馏水中,搅拌至澄清即可。将5xTBE缓冲液稀释10倍即得到0.5xTBE缓冲液,取50ml贮存液加入450ml蒸馏水后即得到500ml工作液。
1%琼脂糖凝胶:使用电子天平称取0.5g的琼脂糖置于烧杯中,加入50ml 0.5xTBE缓冲液中搅拌,并使用微波炉加热煮沸至琼脂糖充分溶解,在溶液冷却至55度后加入EB终结者,充分溶解后铺入胶板,冷却30min。
加样后在0.5xTBE缓冲液中电泳,条件为:110V,40min.
PCR产物琼脂糖电泳示意图如图3所示。
实施例3,食管鳞癌组织及血清外泌体has_circ_0081964的临床诊断价值
本发明纳23名食管鳞癌非转移病人和31名转移病人,收集其年龄、性别、肿瘤大小、位置、分化程度、淋巴结转移、远处转移、TNM分期、组织学类型等基本资料,检测其组织中has_circ_0081964表达水平。同时检测13名非转移患者和14名转移患者的血清中的has_circ_0081964表达水平。
数据分析:本实验数据采用相对定量的分析方法,以β-actin为内参基因(引物序列如SEQ ID NO:4和5所示),以△CT=CThsa_circ_001477-CTβ-actin表示各样本检测数值,比较不同组别的差异,并以GraphPad Prism和SPSS16.0进行分析。
结果:
食管鳞癌转移患者与非转移患者组织与血清血清外泌体hsa_circ_0081964表达差异示意图如图4所示。
组织及血清外泌体hsa_circ_0081964对食管鳞癌转移情况诊断的特异性和灵敏度示意图如图5所示。
本发明提供的食管鳞癌组织及血清外泌体has_circ_0081964作为食管鳞癌诊断标志物及其应用。本发明提供了一种食管鳞癌诊断试剂盒,采用特异性circRNA引物,可以用于检测has_circ_0081964。本发明为食管鳞癌的诊断及淋巴结转移情况提供了一种方便可行的检查方法,为临床分期和治疗方案的选择提供了帮助。
序列表
<110> 江苏省肿瘤防治研究所(江苏省肿瘤医院)
<120> 一种食管鳞癌转移组织及血清外泌体标志物及其应用
<140> 2020101490183
<141> 2020-03-05
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 314
<212> DNA
<213> Homo sapiens
<400> 1
ggttttggcc aaattgggcg agggcacaaa ataaccactt accccttctc accgaggaag 60
agcgggagaa agggtatggc acagtcacaa gggtgggtga aaagatacat caaggccttt 120
tgtaaaggct tctttgtggc ggtgcctgtg gcagtgactt tcttggatcg ggtcgcctgt 180
gtggcaagag tagaaggagc atcgatgcag ccttctttga atcctggggg gagccagtca 240
tctgatgtgg tgcttttgaa ccactggaaa gtgaggaatt ttgaagtaca ccgtggtgac 300
attgtatcat tggt 314
<210> 2
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gtgcttttga accactggaa ag 22
<210> 3
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
catacccttt ctcccgctct 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
gaaatcgtgc gtgacattaa 20
<210> 5
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
aaggaaggct ggaagagtg 19
Claims (7)
1.检测hsa_circ_0081964的试剂在制备利用组织或血清外泌体诊断食管鳞癌淋巴结转移情况的试剂中的应用。
2.根据权利要求1所述的应用,其特征在于所述的试剂为hsa_circ_0081964特异性引物。
3.根据权利要求2所述的应用,其特征在于所述的hsa_circ_0081964特异性引物序列如SEQ ID NO.2和SEQ ID NO.3所示。
4.一种食管鳞癌转移情况的血清外泌体辅助诊断试剂盒,其特征在于包含SEQ IDNO.2和SEQ ID NO.3所示的hsa_circ_0081964特异性引物。
5.根据权利要求4所述的试剂盒,其特征在于所述的试剂盒包含两部分:
A.血清外泌体circRNA提取试剂,包括:
(1)提取血清外泌体所需试剂:GSTM Exosome Isolation
Reagent;
(2)提取外泌体circRNA所需试剂:氯仿、无水乙醇、miRNeasy Serum/Plasma Kit;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂,
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及β-Actin特异性引物。
6.一种食管鳞癌转移情况的组织辅助诊断试剂盒,其特征在于包含SEQ ID NO.2和SEQID NO.3所示的hsa_circ_0081964特异性引物。
7.一种食管鳞癌转移情况的组织辅助诊断试剂盒,其特征在于所述的试剂盒包含两部分:
A.提取组织circRNA所需试剂,包括:TrIzol Reagent、氯仿、异丙醇;
B.hsa_circ_0081964定量检测试剂:
(1)RNA逆转录试剂,
(2)qPCR试剂:包括所述的hsa_circ_0081964特异性引物及B-actin特异性引物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010149018.3A CN112195239B (zh) | 2020-03-05 | 2020-03-05 | 一种食管鳞癌转移组织及血清外泌体标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010149018.3A CN112195239B (zh) | 2020-03-05 | 2020-03-05 | 一种食管鳞癌转移组织及血清外泌体标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112195239A CN112195239A (zh) | 2021-01-08 |
CN112195239B true CN112195239B (zh) | 2024-02-23 |
Family
ID=74004847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010149018.3A Active CN112195239B (zh) | 2020-03-05 | 2020-03-05 | 一种食管鳞癌转移组织及血清外泌体标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112195239B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112877434A (zh) * | 2021-02-22 | 2021-06-01 | 南充市中心医院 | 一组用于检测食管癌组织的circRNA标志物、引物及其应用和含有其的试剂盒 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2774519T3 (es) * | 2015-09-29 | 2020-07-21 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Un método para diagnosticar una enfermedad mediante la detección de ARNcirc en fluidos corporales |
-
2020
- 2020-03-05 CN CN202010149018.3A patent/CN112195239B/zh active Active
Non-Patent Citations (2)
Title |
---|
Genome-Wide Catalogue of Chromosomal Aberrations in Barrett"s Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis;Jian Gu 等;《Cancer Prev Res》;20100930;第3卷(第9期);第1176-1186页 * |
食管鳞状细胞癌多组学数据的整合分析及全基因组关联研究数据挖掘;谭文乐;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20180215;第E072-515页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112195239A (zh) | 2021-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106591428B (zh) | 一种胃癌新型分子标记物hsa_circ_0001017的检测及应用 | |
CN109609630B (zh) | 用于早期胃癌诊断的分子标志物及其应用 | |
CN107012145A (zh) | 一种长非编码rna及其在诊断/治疗胆管癌中的应用 | |
CN109055555B (zh) | 一种肺癌早期转移诊断标志物及其试剂盒和应用 | |
CN112195239B (zh) | 一种食管鳞癌转移组织及血清外泌体标志物及其应用 | |
CN114606321A (zh) | 一种胃癌血浆外泌体circRNA标志物及其试剂盒和应用 | |
CN108866187B (zh) | 一种与肺癌辅助诊断相关的长链非编码rna标志物及其应用 | |
CN110699454A (zh) | 检测样本中mll5基因相对表达量的寡核苷酸、方法和试剂盒 | |
CN105274100B (zh) | 人TWIST1/Vimentin基因甲基化检测标志物及试剂盒 | |
CN113652490A (zh) | 一种用于膀胱癌早期筛查和/或预后监测的引物探针组合及试剂盒 | |
CN109536502B (zh) | 一种适用于妊娠滋养细胞肿瘤患者血浆外泌体miRNA的PCR内参 | |
CN110760586A (zh) | 一种人血浆fhit基因甲基化的检测试剂盒和检测方法 | |
CN106939354B (zh) | miRNA-4530作为肺癌诊断标志物的应用 | |
CN114410795A (zh) | 基于miRNA特征标记的肝癌早期检测 | |
CN109439655B (zh) | 适用于超微量细胞核酸提取的试剂盒及方法 | |
CN106929599B (zh) | miRNA-6126作为肺癌诊断标志物的应用 | |
CN108676880B (zh) | 一种人血清afp阴性肝细胞癌检测试剂盒 | |
CN111575374A (zh) | 用于早期胰腺肿瘤检测分子标志物、其检测方法及应用 | |
CN110699450A (zh) | miRNA生物标志物在肝脏疾病诊断和预后判断中的应用 | |
CN111876487B (zh) | 一种基于环状rna的肿瘤标志物、特异性检测引物及分子检测方法和在胃癌诊断中的应用 | |
CN115786503B (zh) | 胃癌早期筛查的dna甲基化标志物组合及试剂盒 | |
CN112725448B (zh) | 人Circ-DNAH14在非小细胞肺癌中的应用及试剂盒 | |
CN114657251B (zh) | 外泌体miRNA-485-3p和miRNA-885-5p作为肝癌诊断标志物的应用 | |
CN116064788B (zh) | 乳腺癌早期筛查的多重基因甲基化检测荧光定量pcr试剂盒 | |
CN112322737B (zh) | 肾癌早期筛查基因v21-j26检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |